A randomized, controlled, open-label, phase 2 study of Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma
- Alamgeer, Muhammad (Primary Chief Investigator (PCI))
Project: Research
Project: Research